Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

April 30, 2014

Conditions
Prevent Bleeding in Major Surgery
Interventions
BIOLOGICAL

human VWF/FVIII concentrate

intravenous infusion. Dose based on subject's individual invivo-recovery

Trial Locations (15)

1233

SHAT Joan Pavel, Sofia

2193

Hemophilia Comprehensive Care Center, Johannesburg

20122

Granda Ospedale Maggiore Policlinico, Milan

27599

UNC-CH Comprehensive Hemophilia Center, Chapel Hill

35100

Ege University, Izmir

36100

ULSS6 Vicenza Ematologia, Vicenza

46260

Indiana Hemophilia and Thrombosis Center, Indianapolis

50133

Azienda Ospedaliero Universitaria Careggi, Florence

53201

Blood Center of Wisconsin, Milwaukee

300011

Louis Turcanu Childrens Emergency Hospital, Timișoara

411004

Sahyadri Specialty Hospital, Pune

632004

Christian Medical College, Vellore

PC123

Sultan Quaboos University Hospital, Muscat

0.-776

Instytut Hematologii i Transfuzjologii, Warsaw

022328

Fundeni Clinical Institute, Bucharest

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Octapharma

INDUSTRY

NCT01365546 - Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery | Biotech Hunter | Biotech Hunter